- Home
- Products
COMETRIQ (Cabozantinib)
COMETRIQ (Cabozantinib)
- Medicine Name: COMETRIQ
- Generic Name: Cabozantinib
- Dosage Form & Strength: Capsules – 20 mg and 80 mg
- Manufactured By: AstraZeneca Pharmaceuticals LP
- FDA Approval Date: Yes
- European Approval (Brand: Cabometyx): Yes
COMETRIQ (Cabozantinib) is a tyrosine kinase inhibitor used for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).
It works by targeting and inhibiting multiple tyrosine kinases involved in tumor growth, angiogenesis, and metastatic progression, including c-Met, VEGFR2, AXL, and RET. By doing so, it may slow down or stop the growth and spread of cancer cells and the formation of new blood vessels around tumors.
Click here to download full prescribing information.
Required Documentation for Import to India:
- Valid prescription from a qualified medical practitioner
- Relevant diagnostic reports
- Government-issued ID proof of the patient
- Import permit, if required by law
Availability in India:
COMETRIQ is not approved for commercial sale in India. However, it may be accessed under the Named Patient Import program. Delivery can be facilitated across cities including Mumbai, Delhi, Chennai, Hyderabad, Bangalore, Ahmedabad, Pune, Chandigarh, Jaipur, and others.
No generics or biosimilars of COMETRIQ (Cabozantinib) are currently available anywhere in the world.
Global Rare Meds sources COMETRIQ from internationally accredited suppliers in regions such as the USA, Canada, Europe, and Australia.
Medications are dispatched from our fulfillment center in Ambernath, Thane District
Orders are processed upon verification of documents by licensed pharmacists
Delivery is ensured with proper documentation, packaging, and temperature control
We guarantee authentic medicines, regulatory compliance, and timely dispatch across India and global locations.
What is the generic name of COMETRIQ?
Cabozantinib
Who manufactures COMETRIQ?
AstraZeneca Pharmaceuticals LP
What is COMETRIQ used for?
COMETRIQ is used to treat metastatic medullary thyroid cancer (MTC).
Is COMETRIQ approved by the FDA and European Authorities?
Yes, it is FDA-approved and is approved in Europe under the brand name Cabometyx.
What are the available strengths and dosage forms?
COMETRIQ is available in 20 mg and 80 mg capsules.
What are the storage conditions for COMETRIQ?
Store at 20°C to 25°C (68°F to 77°F). Excursions permitted between 15°C to 30°C (59°F to 86°F).
Is COMETRIQ available in generic form?
No, there are no generics or biosimilars currently available.
How can I order COMETRIQ in India?
You will need a valid prescription and documentation. Contact Global Rare Meds to initiate the process.
How much does COMETRIQ cost in India?
For pricing and availability, contact:
Phone: +91-99675 15602
WhatsApp: +91-99675 15602
Email: info@globalraremeds.com
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
